drugset / Trial / NCT00079924

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

NCT00079924

Phase 4 Completed 200 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.

Timeline

Start
2004-11
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule
Subject Raloxifene Other / unclassified
Subject Teriparatide Protein / enzyme biologic 20 ug